Skip to Content

Franklin Biotechnology Discovery A FBDIX

Analyst rating as of
NAV / 1-Day Return
140.85  /  1.20 %
Total Assets
1.3 Bil
Adj. Expense Ratio
0.980%
Expense Ratio
0.980%
Fee Level
Low
Longest Manager Tenure
24.21 years
Category
Health
Investment Style
Mid Blend
Min. Initial Investment
1,000
Status
Open
TTM Yield
0.00%
Turnover
47%
Premium

Morningstar’s Analysis

Will FBDIX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

A tough 2021 is a lesson in biotech risk.

Summary

| |

Franklin Biotechnology Discovery benefits from an experienced team, but limited resources and an undifferentiated process earn the fund a Morningstar Analyst Rating of Neutral.

Unlock our full analysis with Morningstar Premium